Crossmark

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

Crossref DOI link: https://doi.org/10.1038/nm.4369

Published Online: 2017-07-17

Published Print: 2017-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xue, Yaohua

Martelotto, Luciano

Baslan, Timour

Vides, Alberto

Solomon, Martha

Mai, Trang Thi

Chaudhary, Neelam

Riely, Greg J

Li, Bob T

Scott, Kerry

Cechhi, Fabiola

Stierner, Ulrika

Chadalavada, Kalyani

de Stanchina, Elisa

Schwartz, Sarit

Hembrough, Todd

Nanjangud, Gouri https://orcid.org/0000-0002-8547-1957
Berger, Michael F

Nilsson, Jonas

Lowe, Scott W

Reis-Filho, Jorge S

Rosen, Neal

Lito, Piro
License Information

Text and Data Mining valid from 2017-07-17
More Information

Article History

Received: 3 May 2017

Accepted: 15 June 2017

First Online: 17 July 2017

Competing interests

: P.L. is listed as an inventor on a patent application filed by MSKCC that incorporates discoveries described in the manuscript. N.R. is on the scientific advisory board, and has received grant support from, Chugai Pharmaceutical and is on the SAB of Astra-Zeneca, Beigene and Kura. S.S., T.H., K.S. and F.C. are employees of NantOmics.